Compare OFG & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OFG | NNNN |
|---|---|---|
| Founded | 1964 | 2021 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.5B |
| IPO Year | N/A | 2025 |
| Metric | OFG | NNNN |
|---|---|---|
| Price | $41.46 | $32.20 |
| Analyst Decision | Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $45.75 | N/A |
| AVG Volume (30 Days) | ★ 258.0K | 33.4K |
| Earning Date | 01-22-2026 | 04-28-2026 |
| Dividend Yield | ★ 2.90% | N/A |
| EPS Growth | ★ 6.55 | N/A |
| EPS | ★ 4.40 | 0.06 |
| Revenue | ★ $624,004,000.00 | $6,920,153.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $1.02 | N/A |
| P/E Ratio | ★ $9.39 | $584.00 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $33.15 | $5.18 |
| 52 Week High | $46.11 | $55.65 |
| Indicator | OFG | NNNN |
|---|---|---|
| Relative Strength Index (RSI) | 51.97 | 53.52 |
| Support Level | $40.91 | $27.32 |
| Resistance Level | $42.04 | $35.45 |
| Average True Range (ATR) | 0.71 | 3.97 |
| MACD | -0.10 | -0.10 |
| Stochastic Oscillator | 46.08 | 53.09 |
OFG Bancorp is a financial holding company, through its subsidiaries provides banking and financial services. It operates through three segments namely Banking, Wealth Management, and Treasury. It serves to clients such as commercial, consumer, auto, and mortgage lending, checking and savings accounts, financial planning, insurance, financial services, and investment brokerage, and corporate and individual trust and retirement services. The company derives maximum revenue from Banking Segment. It provides services in the region of Puerto Rico.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. It offers laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions to detect a wide range of biomarkers associated with critical medical domains encompassing infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Its product portfolio comprises AF-1200 Fluorescence Immunoassay Analyzer, SHA-100 Dry Chemistry Analyzer, Ferritin Rapid Test Kit, Dengue NS1 Rapid Test, Multi-HBV Rapid Test, COVID-19 Test Kit (Real-time PCR), and others. Geographically, the company generates maximum revenue from the European Union, followed by South America, Asia Pacific, North America, and other regions.